Assembly Biosciences Inc  

(Public, NASDAQ:ASMB)   Watch this stock  
Find more results for NASDAQ:VTUS
+0.21 (2.54%)
Real-time:   11:05AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 8.31 - 8.49
52 week 4.25 - 23.45
Open 8.31
Vol / Avg. 700.00/25,787.00
Mkt cap 90.39M
P/E     -
Div/yield     -
EPS -4.12
Shares 10.65M
Beta 0.12
Inst. own 13%

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -43.38% -81.38%
Return on average equity -46.36% -91.73%
Employees 10 -
CDP Score - -


99 Hudson St Fl 5
NEW YORK, NY 10013-2993
United States - Map
+1-212-5544388 (Phone)
+1-646-7065101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Assembly Biosciences Inc, formerly Ventrus Biosciences, Inc. is a development-stage specialty pharmaceutical company. The Company is focused on the development of late-stage and pre-clinical prescription drugs and biologics, for gastrointestinal disorders. The Company�s product portfolio consists of two late stage assets: VEN 307 (topical diltiazem) for relief from pain associated with anal fissures and VEN 308 (topical phenylephrine) for the treatment of fecal incontinence. The Company also is developing a colonic delivery mechanism (VEN 310), which is a PH sensitive system to deliver bacteria, complex proteins, viral antigens, small molecules and other treatments precisely to the colon. In addition to VEN 307, VEN 308 and VEN 310, the Company intends to pursue the in-licensing and acquisition of other development stage, as well as pre-clinical assets.

Officers and directors

Russell H. Ellison M.D. Chairman of the Board, Chief Executive Officer
Age: 66
Bio & Compensation  - Reuters
Derek A. Small President, Chief Operating Officer, Director, Budget Chief
Bio & Compensation  - Reuters
David J. Barrett CPA Chief Financial Officer
Age: 38
Bio & Compensation  - Reuters
Lee D. Arnold Chief Scientific Officer
Bio & Compensation  - Reuters
Uri A. Lopatin M.D. Vice President - Research & Development, Chief Medical Officer
Bio & Compensation  - Reuters
Richard DiMarchi Director
Bio & Compensation  - Reuters
William Ringo Director
Bio & Compensation  - Reuters
Anthony E. Altig Independent Director
Age: 58
Bio & Compensation  - Reuters
Mark Auerbach CPA Independent Director
Age: 75
Bio & Compensation  - Reuters
Joseph Felder M.D. Independent Director
Age: 53
Bio & Compensation  - Reuters